Study #2017-0935
A Phase 3 randomized, open label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade?), lenalidomide (Revlimid?) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patient
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Physician name:
Robert Orlowski
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-338-0349
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.